On December 18, 2017 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018. David A. Ricks, Lilly’s chairman and chief executive officer, will participate in a fireside chat at 8:00 a.m., Eastern time (Press release, Eli Lilly, DEC 18, 2017, View Source [SID1234522682]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On December 18, 2017 Chugai Pharmaceutical Co., Ltd. (Head office: Tokyo; Chairman & CEO: Osamu Nagayama; "Chugai") reported that it will launch the photodynamic diagnostic agent, "ALAGLIO Divided Granules 1.5g" ("this Agent") on December 19th (Press release, Chugai, DEC 18, 2017, View Source [SID1234522677]). This Agent was developed by SBI Pharmaceuticals Co., Ltd., (Head office: Tokyo; Representative Director & President: Yoshitaka Kitao; "SBI Pharma"), a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA (5-Aminolevulinic acid) and received a manufacturing and marketing approval on September 27th, 2017 for the indication of "visualization of non-muscle invasive bladder cancer during transurethral resection" and was listed on the National Health Insurance reimbursement price list on November 22nd.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Agent for photodynamic diagnosis (PDD) works because the site of the tumor lesion emits red fluorescence when the metabolite of the Agent, protoporphyrin IX, is irradiated with blue light. ALAGLIO is an orphan drug and the first in the world to be approved for this indication. Combining PDD to the transurethral resection of bladder tumors (TURBT) is expected to facilitate the detection of non-muscle invasive bladder cancer and be clinically useful in preventing post-TURBT progression and recurrence.

Chugai and SBI Pharma are dedicated to providing information to ensure that "ALAGLIO Divided Granules 1.5g" is used appropriately and can make an even greater contribution to the treatment of patients with bladder cancer.

5-Aminolevulinic acid (5-ALA):
An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

Transurethral resection of the bladder tumor (TURBT):
A method to insert a surgical endoscope (cystoscope) from the urethra without laparotomy, and resect the tumor while preserving the bladder function.

Non-muscle invasive bladder cancer:
The bladder cancer of a relatively early stage, without invading muscular layer of urinary bladder. It accounts for about 70% of all types of the bladder cancer*. The initial treatment for this type of cancer is primarily TURBT, aiming at the preservation of the bladder function. However, TURBT with a conventional white light source only results in the recurrence with the ratio of 31-78% within 5 years after the operation**.
* Edited by The Japanese Urological Association; Guideline for the Diagnosis and Treatment of the Bladder Cancer 2015 (Igakutosho-shuppan Ltd.); 25
** Sylvester RJ, et al. (2006) Eur Urol; 49: 466-77

Drug Information

Brand name: ALAGLIO Divided Granules 1.5g

Generic name: Aminolevulinic acid hydrochloride

Indications:
Diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection

Dosage and administration:
The recommended dose for adult patients is 20mg of 5-aminolevulinic acid hydrochloride per kg body weight, dissolved in water and orally administered to the patient 3 hours (range: 2-4 hours) before the insertion of a cystoscope to the bladder

Storage: Protection from light, Store at room temperature

Date of approval: September 27, 2017

Date of NHI reimbursement price listing: November 22, 2017

Date of launch: December 19, 2017

Drug price: JPY 74,873.70/ one 1.5g packet
Trademarks used or mentioned in this release are protected by law.

On December 18, 2017 Sorrento Therapeutics, Inc. presented Corporate Presentation (Presentation, Sorrento Therapeutics, DEC 18, 2017, View Source [SID1234522684]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 18, 2017 BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that the first patient was dosed in a pivotal Phase 2 clinical trial of pamiparib (BGB-290), an investigational PARP inhibitor, in Chinese patients with advanced ovarian cancer (Press release, BeiGene, DEC 18, 2017, View Source;p=RssLanding&cat=news&id=2323078 [SID1234522679]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce the initiation of the first pivotal trial of pamiparib in China. Clinical development began in Australia in July 2014 and in China in December 2016. Pamiparib is being evaluated in several global clinical trials in a broad range of indications, both as monotherapy and in combination with tislelizumab (BGB-A317), our anti-PD-1 antibody, with chemotherapy or with radiotherapy. We look forward to advancing pamiparib in China, where no PARP inhibitor has been approved," commented John V. Oyler, Founder, Chief Executive Officer, and Chairman of BeiGene.

"Patients with advanced ovarian cancer who harbor a germline BRCA mutation will be recruited to this study. Patients in China have limited treatment options, especially following platinum-based therapy, despite the multiple approvals of PARP inhibitors in other regions of the world," commented Amy Peterson, M.D., Chief Medical Officer for Immuno-Oncology of BeiGene.

The pivotal Phase 2 single-arm, open-label, multi-center trial is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic profile of pamiparib in patients with high-grade ovarian cancer, including fallopian cancer or primary peritoneal cancer, harboring a known or suspected deleterious germline BRCA1/2 mutation. This trial plans to enroll approximately 100 patients who have received at least two previous lines of therapy in the advanced or metastatic setting, and will be divided into two cohorts according to their platinum-sensitivity status. The trial’s primary endpoint is objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1), as assessed by independent radiology review. Secondary endpoints include ORR as assessed by investigators, progression-free survival, duration of response, overall survival, disease control rate, best overall response, clinical benefit rate, safety, tolerability, and pharmacokinetic profile. Professor Xiaohua Wu of the Fudan University Cancer Center is the lead principal investigator of the trial.

About Pamiparib

Pamiparib (BGB-290) is an investigational inhibitor of PARP1 and PARP2 which demonstrated pharmacological properties such as brain penetration and PARP–DNA complex trapping in preclinical models. Pamiparib is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies.

On December 18, 2017Abbott (NYSE: ABT) reported that it will present its fourth-quarter 2017 financial results on Wednesday, Jan. 24, 2018, before the market opens (Press release, Abbott, DEC 18, 2017, View Source [SID1234522685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.